Clinical Data

Dr. Bruce Leuchter, CEO of Neurvati Neurosciences, explains why psychedelics continues to be an area of interest.

Dr. Jaspal Singh explains some of the barriers that prevent cancer patients from getting biomarker testing early in their treatment journey.

Avak Kahvejian, PhD, a general partner with biotech incubator Flagship Pioneering, discusses how AI is rearchitecting methods—and mindsets—in drug discovery and development.

Strategies for biopharma in integrating agentic AI—to achieve incremental gains in efficiency, while delivering meaningful progress in how data insights inform commercial decision-making.

Health plans face challenges in risk arrangements for orphan drugs, but increasing competition may open doors for innovative pricing strategies.

Following the discontinuation of ALLO-647 due to a treatment-related death, Allogene will move forward with a streamlined outpatient regimen aimed at accelerating enrollment and regulatory review in the Phase II ALPHA3 trial (NCT06500273).

Organizations commonly navigate outdated systems that make collaboration harder and breakthroughs slower, causing delays, missed insights, and costly rework.

A global survey of scientists and informaticians reveals growing AI investment across the biopharma value chain, but highlights gaps in data integration, standardization, and infrastructure that threaten to stall progress.

Cancer patients’ journeys are complex and the benefit of a drug goes well beyond survival, even in cases of incurable and/or metastatic cancer.

Researchers are still studying the impact of going off a GLP-1 medication.

The CEO of Connect Biopharma discusses the unique challenges that patients with asthma and COPD face.

Bharat Awsare discusses a paradigm shift he sees in how the industry is designing and discovering new treatments.

In today’s environment, aligning the Target Product Profile with the appropriate Value Evidence Archetype is not just good practice, it is a strategic imperative.

Poor investigator site selection remains a significant driver of spiraling costs and inefficiencies in clinical development.

Genovese discusses recent data that shows Omvoh’s effectiveness at treating IBD.

The ability to predict side effects such as nausea before starting treatment represents a paradigm shift in precision medicine.

Meeting the growing need and demand for fast information to make optimal and timely treatment decisions.

The argument for weighing clinical points more heavily in the access equation.

A session dives into the trends surrounding specialty drugs and therapies, along with providing an overview of the drug development landscape.

CMS’ draft guidance on real-world data study protocols marks a significant move toward transparency and rigor in Medicare coverage decisions.

Key trends in healthcare communication to build trust between healthcare providers and their patients.

These therapies may provide more stable treatments than stem cell therapies.

Traditional approaches to HCP segmentation are no longer sufficient. The challenge now is to maintain personalization at scale while managing large territories and diverse customer bases.